G. Emons

发表

Exposure of MCF-7 Breast Cancer Cells to Electromagnetic Fields Up-Regulates the Plasminogen Activator System

R. Girgert, G. Emons, V. Hanf, 2009, International Journal of Gynecologic Cancer.

Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts

L. Hofbauer, K. Frosch, G. Emons, 2005, Journal of cellular biochemistry.

Low leptin levels predict amenorrhea in underweight and eating disordered females

H Remschmidt, J. Hebebrand, H. Remschmidt, 1997, Molecular Psychiatry.

Interactions of ovarian steroids with pituitary adenylate cyclase-activating polypeptide and GnRH in anterior pituitary cells.

G. Emons, O. Ortmann, K. Diedrich, 1999, European journal of endocrinology.

Effects of progesterone on gonadotropin-releasing hormone receptor concentration in cultured estrogen-primed female rat pituitary cells

G. Emons, O. Ortmann, J. Nill, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Inhibitory effects of the antiprogestin, RU 486, on progesterone actions and luteinizing hormone secretion in pituitary gonadotrophs.

K. Catt, G. Emons, O. Ortmann, 1989, Journal of steroid biochemistry.

Modulation of gonadotropin-releasing hormone receptor concentration in cultured female rat pituitary cells by estradiol treatment.

G. Emons, O. Ortmann, P. Ball, 1988, Journal of steroid biochemistry.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

A. Reuss, S. Hauptmann, N. Arnold, 2013, Geburtshilfe und Frauenheilkunde.

Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature

M. Meyer-Wittkopf, H. Barth, S. Schmidt, 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Black cohosh: just another phytoestrogen?

G. Emons, V. Viereck, W. Wuttke, 2005, Trends in Endocrinology & Metabolism.

Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis

S. Loibl, J. Huober, A. Hasenburg, 2009, Annals of Surgical Oncology.

Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields

R. Girgert, G. Emons, V. Hanf, 2009, Bioelectromagnetics.

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review

G. Emons, O. Ortmann, K. Kast, 2020, Archives of Gynecology and Obstetrics.

The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women.

G. Emons, P. Hadji, K. Schulz, 2000, European journal of endocrinology.

Identification of drivers of breast cancer invasion by secretome analysis: insight into CTGF signaling

C. Lenz, G. Bauerschmitz, G. Emons, 2020, Scientific Reports.

Uterine Cervical Metastasis of Breast Cancer: A Rare Complication that May be Overlooked

G. Emons, V. Viereck, P. Burfeind, 2003, Oncology Research and Treatment.

Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.

G. Bauerschmitz, G. Emons, C. Gründker, 2016, International journal of oncology.

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

G. Emons, A. Mustea, C. Tempfer, 2020, Cancers.

Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

Michael D Mueller, G. Emons, C. Gründker, 2012, International journal of oncology.

Mesengenic progenitor cells derived from human placenta.

L. Trümper, G. Emons, T. Pukrop, 2004, Tissue engineering.

The diagnosis and treatment of endometrial cancer: progress and controversies.

G. Emons, U. Ulrich, D. Denschlag, 2011, Deutsches Arzteblatt international.

Biology of the gonadotropin-releasing hormone system in gynecological cancers.

G. Emons, C. Gründker, A. Günthert, 2002, European journal of endocrinology.

The influence of menopause and body mass index on serum leptin concentrations.

G. Emons, P. Hadji, K. Schulz, 2000, European journal of endocrinology.

The effect of EUSOMA certification on quality of breast cancer care.

C. Sohn, J. Heil, R. Kimmig, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Significance of Lymph Node Dissection in Gynecological Oncology

G. Emons, 2014, Oncology Research and Treatment.

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review

G. Emons, O. Ortmann, K. Kast, 2021, Journal of Cancer Research and Clinical Oncology.

Interactions between radiation and endocrine therapy in breast cancer.

C. Hess, R. Hermann, G. Emons, 2002, Endocrine-related cancer.

Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)

Jae-Weon Kim, C. Schade-Brittinger, G. Emons, 2021, International Journal of Gynecological Cancer.

Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma – an anachronism?

G. Emons, 2020, Journal of gynecologic oncology.

The Diagnosis and Treatment of Endometrial Cancer

G. Emons, 2011 .

Value of sonomorphological criteria of the endometrium in women with postmenopausal bleeding: a multivariate analysis

W. Sauerbrei, G. Emons, H. Madjar, 2002, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

T. Park-Simon, G. Emons, F. Thiel, 2016, Gynecologic oncology.

Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).

H. Sindermann, J. Sehouli, G. Emons, 2014, Gynecologic oncology.

Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.

M. Beckmann, L. Kiesel, G. Emons, 2007, Gynecologic oncology.

Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol

R. Girgert, G. Emons, C. Gründker, 2014, BMC Cancer.

Elevated Concentrations of Serum Relaxin are Associated with Metastatic Disease in Breast Cancer Patients

L. Trümper, T. Hagemann, G. Emons, 2004, Breast Cancer Research and Treatment.

Inhibition of SDF-1/CXCR4-induced epithelial–mesenchymal transition by kisspeptin-10

G. Bauerschmitz, G. Emons, C. Gründker, 2015, Breast Cancer Research and Treatment.

Kisspeptin-10 Inhibits Stromal-Derived Factor 1–Induced Invasion of Human Endometrial Cancer Cells

G. Emons, C. Gründker, E. Schmidt, 2014, International Journal of Gynecologic Cancer.

Primary and salvage therapy with LH-RH analogues in ovarian cancer.

G. Emons, K. Schulz, K. Schulz, 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

L. Hofbauer, K. Frosch, G. Emons, 2003, The Journal of clinical endocrinology and metabolism.

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

L. Hofbauer, K. Frosch, G. Emons, 2002, Biochemical and biophysical research communications.

G. Emons, B. Hinney, G. Fleckenstein, 2001 .

Significant Changes in Circulating Plasma Levels of IGF1 and IGFBP3 after Conventional or Dose-Intensified Adjuvant Treatment of Breast Cancer Patients with one to three Positive Lymph Nodes

R. Kreienberg, N. Gebauer, J. Blohmer, 2007, The International journal of biological markers.

Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes.

R. Kreienberg, N. Gebauer, J. Blohmer, 2007, The International journal of biological markers.

Intra‐operative introital ultrasound in Burch colposuspension reduces post‐operative complications

G. Emons, W. Hatzmann, V. Viereck, 2005, BJOG : an international journal of obstetrics and gynaecology.

Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review

G. Emons, O. Ortmann, K. Kast, 2020, Archives of Gynecology and Obstetrics.

Hormone Replacement Therapy and Endometrial Cancer

G. Emons, T. Krauss, B. Hinney, 2004, Oncology Research and Treatment.

Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.

G. Emons, O. Ortmann, J. D. Neill, 1995, Cancer research.

Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.

T. Schlott, A. Schally, G. Emons, 2004, American journal of obstetrics and gynecology.

The influence of serum leptin concentration on bone mass assessed by quantitative ultrasonometry in pre and postmenopausal women.

G. Emons, P. Hadji, K. Schulz, 2003, Maturitas.

The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women.

G. Emons, P. Hadji, K. Schulz, 2000, Maturitas.

Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts

L. Hofbauer, G. Emons, C. Gründker, 2002, Journal of cellular biochemistry.

Weak estrogenic activity of phenol red in the pituitary gonadotroph: re-evaluation of estrogen and antiestrogen effects.

G. Emons, O. Ortmann, R. Sturm, 1990, Journal of steroid biochemistry.

Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.

G. Emons, C. Gründker, A. Günthert, 2002, Biochemical and biophysical research communications.

Luteinizing hormone‐releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial

A. Schally, U. Löhrs, G. Emons, 1996 .

Membrane‐bound melatonin receptor MT1 down‐regulates estrogen responsive genes in breast cancer cells

R. Girgert, G. Emons, V. Hanf, 2009, Journal of pineal research.

Starving Tumors: Inhibition of Glycolysis Reduces Viability of Human Endometrial and Ovarian Cancer Cells and Enhances Antitumor Efficacy of GnRH Receptor-Targeted Therapies

G. Emons, C. Gründker, M. Reutter, 2013, International Journal of Gynecologic Cancer.

Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.

B. Pieske, G. Emons, D. Hilfiker-Kleiner, 2008, American journal of obstetrics and gynecology.

Assessment by quantitative ultrasonometry of the effects of hormone replacement therapy on bone mass.

G. Emons, C. Wüster, P. Hadji, 2000, American journal of obstetrics and gynecology.

Ovarian steroids modulate endothelin-induced luteinizing hormone secretion from cultured rat pituitary cells.

K. Catt, S. Stojilkovic, G. Emons, 1993, Endocrinology.

Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.

G. Emons, C. Gründker, A. Günthert, 2004, Anticancer research.

Combination of Anti-Estrogenic Therapy with Radiation in Breast Cancer: Simultaneous or Sequential Treatment?

C. Hess, R. Hermann, G. Emons, 2005, Oncology Research and Treatment.

Metabolic clearance rates of catechol estrogens in rats.

G. Emons, P. Ball, J. Teichmann, 1983, Endocrinology.

Effects of catecholestrogens on luteinizing hormone levels in long tem ovariectomized adult rats.

G. Emons, P. Ball, R. Knuppen, 1981, Endocrinology.

Effect of low doses of continuously administered catecholoestrogens on peripheral and central target organs.

G. Emons, P. Ball, U. Gethmann, 1981, Acta endocrinologica.

Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.

G. Emons, C. Gründker, K. Schulz, 2000, Gynecologic oncology.

Growth-Inhibitory Actions of Analogues of Luteinizing Hormone Releasing Hormone on Tumor Cells

A. Schally, G. Emons, O. Ortmann, 1997, Trends in Endocrinology & Metabolism.

Luteinizing Hormone-releasing Hormone ( LHRH ) Inhibits Apoptosis Induced by Cytotoxic Agent and UV-light but not Apoptosis Mediated Through CD 95 in Human Ovarian and Endometrial Cancer Cells

G. Emons, C. Gründker, B. Böttcher, 2009 .

Lynch-Syndrom (HNPCC‑Syndrom)

G. Emons, S. Aretz, 2020, Der Gynäkologe.

Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.

A. Schally, G. Emons, C. Gründker, 2002, American journal of obstetrics and gynecology.

Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019

D. Vordermark, G. Emons, C. Tempfer, 2019, Geburtshilfe und Frauenheilkunde.

Endometrial Cancer

G. Emons, V. Hanf, A. Günthert, 2003, Oncology Research and Treatment.

Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.

G. Emons, C. Gründker, A. Günthert, 2010, Anticancer research.

Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose-window effect.

G. Emons, C. Gründker, A. Schubert, 2010, Gynecologic oncology.

Antiproliferative effects of kisspeptin‑10 depend on artificial GPR54 (KISS1R) expression levels.

G. Emons, C. Gründker, T. Olbrich, 2013, Oncology reports.

Peripartum Cardiomyopathy—A New Treatment Option by Inhibition of Prolactin Secretion

B. Pieske, G. Emons, D. Hilfiker-Kleiner, 2009 .

Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.

B. Ghadimi, G. Emons, C. Gründker, 2011, Oncology reports.

Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.

G. Emons, C. Gründker, V. Viereck, 2001, European journal of endocrinology.

Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.

G. Emons, C. Gründker, R. Millar, 2002, The Journal of clinical endocrinology and metabolism.

Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells

G. Emons, C. Gründker, A. Günthert, 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.

G. Emons, C. Gründker, A. Günthert, 2007, Cancer research.

Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.

G. Emons, C. Gründker, A. Günthert, 2005, European journal of endocrinology.

Effects of Progesterone and Antiprogestins on Gonadotropin Secretion in the Model of Cultured Rat Pituitary Cells

K. Catt, S. Stojilkovic, G. Emons, 1994 .

Hormonal interactions in ovarian cancer.

G. Emons, J. Kavanagh, 1999, Hematology/oncology clinics of North America.

GnRH antagonists in the treatment of gynecological and breast cancers.

G. Emons, C. Gründker, J. Kavanagh, 2003, Endocrine-related cancer.

International Congress on Hormonal Steroids and Hormones and Cancer GnRH antagonists in the treatment of gynecological and breast cancers

C. Verschraegen, G. Emons, J. Kavanagh, 2003 .

Ovarian steroids modulate gonadotropin-releasing hormone-induced biphasic luteinizing hormone secretory responses and inositol phosphate accumulation in rat anterior pituitary cells and αT3-1 gonadotrophs

G. Emons, O. Ortmann, K. Schulz, 1995, The Journal of Steroid Biochemistry and Molecular Biology.

GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.

G. Emons, C. Gründker, A. Günthert, 2009, Cancer research.

Actions of gonadotropin-releasing hormone analogues in pituitary gonadotrophs and their modulation by ovarian steroids

G. Emons, O. Ortmann, S. König, 2006, The Journal of Steroid Biochemistry and Molecular Biology.

Determination of bladder neck position by intraoperative introital ultrasound in colposuspension: outcome at 6‐month follow‐up

G. Emons, V. Viereck, C. Skala, 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites

G. Emons, V. Viereck, P. Burfeind, 2005, Prenatal diagnosis.

Factor XII deficiency is strongly associated with primary recurrent abortions.

G. Emons, P. Burfeind, H. Köstering, 2003, Fertility and sterility.

Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.

H. Bang, K. Fox, K. Oktay, 2007, The oncologist.

Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues.

G. Emons, C. Gründker, K. Schulz, 2002, American journal of obstetrics and gynecology.

Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines.

G. Emons, O. Ortmann, C. Bürger, 1994, The Journal of clinical endocrinology and metabolism.

The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.

A. Schally, G. Emons, 1994, Human reproduction.

Early onset vulvar Lichen Sclerosus in premenopausal women and oral contraceptives.

G. Emons, G. Knappe, A. Günthert, 2008, European journal of obstetrics, gynecology, and reproductive biology.

Importance of A-ring substitution of estrogens for the physiology and pharmacology of reproduction.

G. Emons, P. Ball, R. Knuppen, 1986, Journal of steroid biochemistry.

Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization.

U. Brinck, B. Gunawan, G. Emons, 2002, Gynecologic oncology.

High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.

A. Schally, G. Emons, O. Ortmann, 1993, The Journal of clinical endocrinology and metabolism.

High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.

A. Schally, G. Emons, O. Ortmann, 1993, Cancer research.

The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer

G. Emons, C. Gründker, 2021, Cells.

Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers.

G. Emons, C. Gründker, A. Huschmand Nia, 2005, Molecular cancer therapeutics.

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.

G. Emons, C. Gründker, V. Viereck, 2004, European journal of endocrinology.

Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata.

G. Emons, G. Vollmer, S. Kullander, 1991, European journal of obstetrics, gynecology, and reproductive biology.

Effects of LHRH-analogues on mitogenic signal transduction in cancer cells 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997.

V. Müller, G. Emons, O. Ortmann, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Hormonal heterogeneity of endometrial cancer.

G. Emons, C. Gründker, A. Günthert, 2008, Advances in experimental medicine and biology.

Overrepresentation of 8q in carcinosarcomas and endometrial adenocarcinomas.

K. Donhuijsen, C. Enders, B. Gunawan, 2004, American journal of clinical pathology.

LH-RH agonists in the treatment of ovarian cancer.

G. Emons, O. Ortmann, K. Schulz, 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH‐agonists in ovarian cancer

G. Emons, O. Ortmann, G. S. Pahwa, 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.

Serum leptin and gonadotropin levels in patients with anorexia nervosa during weight gain

J. Hebebrand, H. Remschmidt, G. Emons, 1999, Molecular Psychiatry.

GnRH analogs reduce invasiveness of human breast cancer cells

K. Frosch, G. Emons, C. Gründker, 2006, Breast Cancer Research and Treatment.

Pentalogy of Cantrell vs. limb body wall complex: differential diagnosis of a severe malformation in early pregnancy.

G. Emons, T. Hawighorst, W. Stein, 2009, Ultraschall in der Medizin.

Allgemeine Grundlagen der Tumorbiologie in der Viszeralchirurgie

G. Emons, M. Grade, M. Ghadimi, 2013, Zentralblatt für Chirurgie – Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie.

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer

Tanja Fehm, Nina Ditsch, Dieter Niederacher, 2016, Journal of Medical Genetics.

Hormonal interactions in endometrial cancer.

G. Emons, G Fleckenstein, G Emons, 2000, Endocrine-related cancer.

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).

A. Oza, S. Pignata, K. Steffensen, 2013, Gynecologic oncology.

Androblastoma of the Ovary: Clinical, Diagnostic and Histopathologic Features

G. Emons, W. Wuttke, R. Osmers, 2001, Oncology Research and Treatment.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors

D. Provencher, J. Ledermann, R. Glasspool, 2014, International Journal of Gynecologic Cancer.

Modulation of cytoplasmic calcium signaling in rat pituitary gonadotrophs by estradiol and progesterone.

K. Catt, S. Stojilkovic, G. Emons, 1992, Endocrinology.

Acute facilitory action of progesterone on gonadotropin secretion of perifused rat pituitary cells.

G. Emons, O. Ortmann, R. Knuppen, 1989, Acta endocrinologica.

Testicular GnRH-receptors and direct effects of a GnRH-agonist on human testicular steroidogenesis.

M. Hammar, G. Emons, F. Petersson, 1989, Scandinavian journal of urology and nephrology.

Recurrence and rapid metastasis formation of a granular cell tumor of the vulva.

B. Gunawan, L. Füzesi, G. Emons, 2003, European journal of obstetrics, gynecology, and reproductive biology.

Sertoli-Leydig cell tumour in a 13-year-old girl

G. Emons, S. Schweyer, B. Hinney, 2011, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium : Requirements for pathology].

E. Steiner, L. Horn, G. Emons, 2019, Der Pathologe.

Funneling before and after anti-incontinence surgery—a prognostic indicator? Part 2: tension-free vaginal tape

G. Emons, V. Viereck, R. Hilgers, 2007, International Urogynecology Journal.

Role of bladder neck mobility and urethral closure pressure in predicting outcome of tension‐free vaginal tape (TVT) procedure

G. Emons, V. Viereck, R. Hilgers, 2006, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Urethral hypermobility after anti-incontinence surgery—a prognostic indicator?

G. Emons, V. Viereck, R. Tunn, 2006, International Urogynecology Journal.

New WHO Classification of Endometrial Hyperplasias.

M. Beckmann, G. Emons, P. Mallmann, 2015, Geburtshilfe und Frauenheilkunde.

Recurrent Pregnancy Loss and Its Relation to FV Leiden, FII G20210A and Polymorphisms of Plasminogen Activator and Plasminogen Activator Inhibitor

G. Emons, B. Zoll, P. Hellstern, 2003, Pathophysiology of Haemostasis and Thrombosis.

Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions

G. Emons, P. Burfeind, J. Neesen, 2003, Acta obstetricia et gynecologica Scandinavica.

Adjuvant treatment for endometrial cancer.

D. Vordermark, G. Emons, 2019, Current opinion in oncology.

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

T. Park-Simon, J. Rau, C. Jackisch, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Placenta percreta in week 10 of pregnancy with consecutive hysterectomy: case report.

G. Emons, M. Höpker, G. Fleckenstein, 2002, Human reproduction.

Modulatory actions of the new antiprogestins ZK 98.299 and ZK 98.734 and of RU 486 on luteinizing hormone secretion and progesterone effects in pituitary gonadotrophs.

G. Emons, O. Ortmann, R. Knuppen, 1990, Journal of steroid biochemistry.

Influence of ARHGAP29 on the Invasion of Mesenchymal-Transformed Breast Cancer Cells

G. Bauerschmitz, G. Emons, C. Gründker, 2020, Cells.

Pharmacological effects of 2- and 4-methyloestradiol as a probe to test the biological importance of 2- and 4-hydroxylation of oestrogens (catecholoestrogen-formation).

G. Emons, P. Ball, R. Knuppen, 1983, Acta endocrinologica.

Effects of antibodies to catecholoestrogens and catecholoestrogen methyl ethers on PMS induced ovulations in immature rats.

G. Emons, P. Ball, C. Schwarzlose, 1982, Acta endocrinologica.

Importance of catecholestrogens in the regulation of the ovarian cycle

G. Emons, P. Ball, R. Knuppen, 2005, Archives of gynecology.

Effects of estradiol and some antiestrogens (Clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture

G. Emons, O. Ortmann, R. Knuppen, 2005, Archives of gynecology.

Biphasic modulation of pituitary sensitivity to GnRH by oestrogens: the effects of A- and D-ring substitution on LH release in cultured pituitary cells.

K. Catt, G. Emons, P. Ball, 1984, Acta endocrinologica.

Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death

G. Emons, C. Gründker, Matthias Läsche, 2020, Frontiers in Oncology.

Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo

G. Emons, C. Gründker, Maike Haase, 2014, Breast Cancer Research and Treatment.

Mortality from esophagectomy for esophageal cancer across low, middle, and high-income countries: An international cohort study.

W. A. Jansen, M. Achiam, R. van Hillegersberg, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.

K. Ulm, J. Blohmer, S. Kümmel, 2006, Anticancer research.

Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.

R. Girgert, G. Emons, C. Gründker, 2018, Oncology letters.

Fulminant Puerperal Sepsis caused by Hemolytic Group A Streptococci and Toxic Shock Syndrome - A Case Report and Review of the Literature.

G. Bauerschmitz, G. Emons, J. Strauchmann, 2014, Geburtshilfe und Frauenheilkunde.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

A. Meindl, R. Schmutzler, M. Kiechle, 2018, BMC Cancer.

CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo

Thomas Hawighorst, G. Emons, C. Gründker, 2010, Breast Cancer Research and Treatment.

Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.

G. Emons, C. Gründker, M. Hellriegel, 2017, Oncology reports.

Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.

R. Girgert, G. Emons, C. Gründker, 2015, International journal of oncology.

LHRH-receptors and LHRH-agonist treatment in ovarian cancer: An overview

G. Emons, O. Ortmann, K. Schulz, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

The Use of GnRH Analogues in Ovarian Cancer

G. Emons, R. Knuppen, G. S. Pahwa, 1990 .

Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.

G. Emons, C. Gründker, A. Günthert, 2004, European journal of endocrinology.

Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer

G. Emons, C. Gründker, 2021, Cells.

New WHO Classification of Endometrial Hyperplasias.

M. Beckmann, G. Emons, P. Mallmann, 2015, Geburtshilfe und Frauenheilkunde.

The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis

G. Emons, C. Gründker, Carsten Gründker, 2017, Front. Endocrinol..

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors

M. Beckmann, H. Sindermann, J. Sehouli, 2014, International Journal of Gynecologic Cancer.

Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer

G. Emons, C. Gründker, 2003, Reproductive biology and endocrinology : RB&E.

Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

G. Emons, C. Gründker, S. Schweyer, 2011, Oncology reports.

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo

G. Emons, C. Gründker, A. Günthert, 2010, Breast Cancer Research.

articleGonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo

G. Emons, C. Gründker, A. Günthert, 2010 .

Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata.

G. Emons, G. Vollmer, R. Knuppen, 1989, Biochemical and biophysical research communications.

Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata.

G. Emons, R. Sturm, R. Knuppen, 1989, European journal of cancer & clinical oncology.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilita

M. Beckmann, R. Kimmig, A. Meindl, 2018, Geburtshilfe und Frauenheilkunde.

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

W. Gaissmaier, P. Hall, D. Eccles, 2021, Breast Care.

Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

G. Bauerschmitz, G. Emons, C. Gründker, 2019, Front. Oncol..

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER

R. Girgert, G. Emons, C. Gründker, 2019, Front. Endocrinol..

Luteinizing Hormone-Releasing Hormone Induces Nuclear Factorκ B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells

G. Emons, C. Gründker, A. Günthert, 2000 .

Luteinizing Hormone-Releasing Hormone Induces Nuclear Factor k B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells

G. Emons, C. Gründker, A. Günthert, 2000 .

Vulvitis granulomatosa and unilateral hypertrophy of the vulva related to Crohn's disease: a case report.

G. Emons, V. Hanf, A. Günthert, 2004, American journal of obstetrics and gynecology.

Modulatory actions of estradiol and progesterone on phorbol ester-stimulated LH secretion from cultured rat pituitary cells

G. Emons, O. Ortmann, Björn Tilse, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Acute effects of oestradiol and progesterone on melittin- and gonadotrophin-releasing hormone-induced LH secretion.

G. Emons, O. Ortmann, R. Knuppen, 1992, The Journal of endocrinology.

Studies on the subcellular mechanisms mediating the negative estradiol effect on GnRH-induced LH-release by rat pituitary cells in culture.

L. Kiesel, G. Emons, O. Ortmann, 1989, Acta endocrinologica.

Inhibitory actions of keoxifene on luteinizing hormone secretion in pituitary gonadotrophs.

K. Catt, G. Emons, O. Ortmann, 1988, Endocrinology.

New Developments in the Treatment of Cervical Cancer

G. Emons, V. Viereck, T. Krauss, 2001, Oncology Research and Treatment.

LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer.

G. Emons, C. Gründker, O. Ortmann, 2000, European journal of endocrinology.

Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.

H. Kölbl, T. Reimer, G. Emons, 2013, Gynecologic oncology.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer

M. Beckmann, R. Kimmig, A. Meindl, 2018, Geburtshilfe und Frauenheilkunde.

Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.

R. Mansel, C. Sohn, J. Heil, 2017, European journal of cancer.

Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database.

M. R. del Turco, J. Heil, R. Kreienberg, 2012, European journal of cancer.

Predictive value of routine circulating soluble endothelial cell adhesion molecule measurements during pregnancy.

H. Augustin, G. Emons, T. Krauss, 2002, Clinical chemistry.

Surgical management of endosalpingiosis with tubovaginal fistulization after hysterectomy by a combined laparoscopic‐vaginal route, and histological findings

U. Brinck, G. Emons, V. Viereck, 2001 .

GNRH-binding-sites in human epithelial ovarian carcinoma

G. Emons, P. Ball, R. Sturm, 1986 .

Postoperative funneling after anti‐incontinence surgery—a prognostic indicator?—part 1: Colposuspension

G. Emons, V. Viereck, C. Skala, 2004, Neurourology and urodynamics.

Pseudo-Meigs Syndrome: Uterine Leiomyoma with Bladder Attachment Associated with Ascitesand Hydrothorax – a Rare Case of a Rare Syndrome

A. Fayyazi, G. Emons, T. Krauss, 2002, Oncology Research and Treatment.

Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells

Volker Hanf, R. Girgert, G. Emons, 2008, Bioelectromagnetics.

Isopropanolic Extract of Black Cohosh Stimulates Osteoprotegerin Production by Human Osteoblasts

L. Hofbauer, K. Frosch, G. Emons, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Cell‐free fetal DNA in specimen from pregnant women is stable up to 5 days

G. Emons, K. Gutensohn, T. Legler, 2011, Prenatal diagnosis.

Palliative Hormonal Treatment in Endometrial Carcinoma

G. Emons, K. Schulz, R. Hackenberg, 1991 .

Stiffness index identifies patients with osteoporotic fractures better than ultrasound velocity or attenuation alone.

G. Emons, C. Wüster, P. Hadji, 1999, Maturitas.

Radioimmunoassay of 2-hydroxyestrone

G. Emons, P. Ball, R. Knuppen, 1978, Steroids.

Hormonal treatment of endometrial cancer

G. Emons, W. Heyl, 2000, Journal of Cancer Research and Clinical Oncology.

Antiproliferative Signaling of Luteinizing Hormone-Releasing Hormone in Human Endometrial and Ovarian Cancer Cells through G Proteinα I-Mediated Activation of Phosphotyrosine Phosphatase.

G. Emons, Carsten Gru Ndker, Peter Vo Lker, 2001, Endocrinology.

Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines.

A. Schally, G. Emons, O. Ortmann, 1996, International journal of oncology.

New Developments in the Hormonal Treatment of Endometrial and Ovarian Cancer

G. Emons, K. Schulz, 1995 .

Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male.

G. Emons, G. Merriam, D. Loriaux, 1986, Journal of steroid biochemistry.

Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates

G. Emons, P. Ball, R. Knuppen, 1982, Steroids.

4-hydroxyestrone, isolation and identification in human urine

G. Emons, P. Ball, R. Knuppen, 1980, Steroids.

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy

R. Girgert, G. Emons, C. Gründker, 2012, Breast Cancer Research and Treatment.

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.

A. Schally, G. Emons, J. Engel, 2011, Current drug delivery.

Cell-free fetal DNA and adverse outcome in low risk pregnancies.

G. Emons, K. Gutensohn, T. Legler, 2013, European journal of obstetrics, gynecology, and reproductive biology.

Inhibition of aerobic glycolysis enhances the anti‐tumor efficacy of Zoptarelin Doxorubicin in triple‐negative breast cancer cells

G. Emons, C. Gründker, M. Hellriegel, 2019, The journal of obstetrics and gynaecology research.

Quantitative ultrasound of the os calcis in postmenopausal women with spine and hip fracture.

G. Emons, P. Hadji, K. Schulz, 2000, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Age Changes of Calcaneal Ultrasonometry in Healthy German Women

G. Emons, U. Albert, P. Hadji, 1999, Calcified Tissue International.

The impact of rectal/bladder filling and applicator positioning on in vivo rectal dosimetry in vaginal cuff brachytherapy using an enhanced therapy setting.

A. Leha, C. Hess, A. Hille, 2019, Brachytherapy.

5201 POSTER The EXpand Study – Effect of Zoledronic Acid on Prevention of Bone Loss, During Extended Adjuvant Therapy With Letrozole in Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer Compared to Letrozole Alone

T. Reimer, G. Emons, J. Hackmann, 2011 .

Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.

G. Emons, C. Gründker, P. Völker, 2001, Endocrinology.

Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152

H. Sindermann, A. Schally, G. Emons, 2009, Neuroendocrinology.

Introital ultrasound of the lower genital tract before and after colposuspension: a 4‐year objective follow‐up

G. Emons, V. Viereck, R. Hilgers, 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[Qualification and education in gynecological oncology].

M. Beckmann, M. Kaufmann, G. Emons, 2006, Zentralblatt fur Gynakologie.

Prostaglandins have no effect on spontaneous and gonadotrophin-releasing hormone stimulated luteinizing hormone release in cultured rat pituitary cells

G. Emons, U. Gethmann, S. Thiessen, 2005, Archives of gynecology.

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

C. Verschraegen, A. Kudelka, Wei Hu, 2003, Gynecologic oncology.

Short-term effects of oestradiol and 4-hydroxyoestradiol on gonadotrophin-releasing hormone induced luteinizing hormone secretion by rat pituitary cells in culture.

G. Emons, O. Ortmann, P. Ball, 1986, Acta endocrinologica.

Hormone Replacement Therapy and Endometrial Cancer

G. Emons, T. Krauss, B. Hinney, 1977, The Lancet.

Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

A. Schally, G. Emons, O. Ortmann, 2012, Archives of Gynecology and Obstetrics.

Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo

G. Emons, C. Gründker, T. Hawighorst, 2011, Breast Cancer Research and Treatment.

Expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression

G. Emons, C. Gründker, A. Schubert, 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

P1014 Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells

G. Emons, C. Gründker, A. Günthert, 2009 .

Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.

A. Schally, G. Emons, F. Kaiser, 2000, International journal of oncology.

Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.

H. Sindermann, A. Schally, M. Kaufmann, 2010, Gynecologic oncology.

378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany

M. Beckmann, J. Sehouli, G. Emons, 2010 .

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.

J. Sehouli, P. Dall, G. Emons, 2010 .

17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.

R. Girgert, G. Emons, C. Gründker, 2017, Oncology reports.